Company Filing History:
3 out of 66 
2 out of 559 
Years Active: 2021-2025
Title: Inventor Spotlight: Kimberly Harrington
Introduction
Kimberly Harrington is a notable inventor based in Seattle, Washington, recognized for her contributions to biomedicine through innovative patented technologies. With two patents to her name, she has made significant advancements in the field of immunotherapy, particularly in the development of molecules that target specific antigens.
Latest Patents
Harrington's latest patents focus on antibodies and chimeric antigen receptors specific for B-cell maturation antigen (BCMA). The first patent describes BCMA-binding molecules, which include anti-BCMA antibodies and various antigen-binding fragments. These molecules, particularly heavy chain variable regions and single-chain antibodies, play a critical role in creating chimeric antigen receptors (CARs). Such advancements hold promise for adoptive cell therapy in treating diseases associated with B-cells.
Her second patent elaborates on the design and function of chimeric receptors, such as CARs, that incorporate BCMA-binding molecules. These engineered receptors have the potential to improve therapeutic responses in treatments that target BCMA, thereby enhancing patient outcomes in clinical settings.
Career Highlights
Kimberly Harrington has built her career through pivotal roles at renowned institutions, including Juno Therapeutics GmbH and Memorial Sloan Kettering Cancer Center. Her work at these organizations has involved cutting-edge research focused on cell therapy and cancer treatment innovations.
Collaborations
Throughout her career, Harrington has collaborated with esteemed colleagues, including Blythe D. Sather and Collin Hauskins. These partnerships enhance the collaborative atmosphere in the field of medical research, fostering breakthroughs that can change patient care.
Conclusion
Kimberly Harrington’s contributions to the field of biotechnology through her patents position her as a leading innovator in the development of effective therapies targeting B-cell maturation antigen. Her ongoing research and collaboration with notable institutions promise to bring forth new therapeutic avenues that can significantly impact the fight against cancer and other related diseases.